Drug Trial Radar · NCT05173142
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
190
Actual
Start
Jan 22, 2022
Primary completion
Jul 17, 2025
Study completion Jan 17, 2026
Sponsor
- Lead sponsor
- Hutchison Medipharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination with Chemotherapy or Toripalimab in Advanced Solid Tumors
Conditions
- Solid Tumor
Interventions
HMPL-453Drug
HMPL-453 administered orally.
gemcitabine and cisplatinDrug
Gemcitabine and Cisplatin administered intravenously.
toripalimabDrug
Toripalimab administered intravenously.
DocetaxelDrug
Docetaxel administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability(Incidence and severity of adverse events (AEs))Time frame: 6 months after the last patient enrolled
- Preliminary efficacy/Objective response rate (ORR)Time frame: up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.